Research progress on phosphodiesterase 4 inhibitors in the treatment of palmoplantar pustulosis
Palmoplantar pustulosis (PPP) is a chronic recurrent inflammatory skin disease. Existing therapeutic methods cannot meet the demand by patients. Phosphodiesterase-4 (PDE-4) is a key enzyme involved in the balance of immunocytes. It acts as a downstream mediator in the signaling pathways of a variety...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
editoiral office of Journal of Diagnosis and Therapy on Dermato-venereology
2024-11-01
|
| Series: | Pifu-xingbing zhenliaoxue zazhi |
| Subjects: | |
| Online Access: | http://pfxbzlx.gdvdc.com/EN/10.3969/j.issn.1674-8468.2024.11.011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Palmoplantar pustulosis (PPP) is a chronic recurrent inflammatory skin disease. Existing therapeutic methods cannot meet the demand by patients. Phosphodiesterase-4 (PDE-4) is a key enzyme involved in the balance of immunocytes. It acts as a downstream mediator in the signaling pathways of a variety of cytokines which are associated with palmoplantar pustulosis and extensively regulate immune responses. Apremilast, as representative of the oral PDE-4 inhibitors, displays superior efficacy in clinical trials against palmoplantar pustulosis. Crisaborole has also been regulate to induce sustained improvement in skin lesions. This article reviews the research progress on PDE-4 inhibitors in treatment of palmoplantar pustulosis. |
|---|---|
| ISSN: | 1674-8468 |